<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062075</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00034</org_study_id>
    <secondary_id>12209B</secondary_id>
    <secondary_id>CDR0000304460</secondary_id>
    <secondary_id>N01CM62201</secondary_id>
    <secondary_id>N01CM17102</secondary_id>
    <secondary_id>U01CA099177</secondary_id>
    <secondary_id>P30CA014599</secondary_id>
    <nct_id>NCT00062075</nct_id>
  </id_info>
  <brief_title>Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 2 Study of Depsipeptide in Patients With Relapsed or Refractory AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well romidepsin works in treating patients with relapsed&#xD;
      or refractory acute myeloid leukemia. Drugs used in chemotherapy, such as romidepsin, work in&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the complete and partial response rate in patients with relapsed or refractory&#xD;
      acute myeloid leukemia treated with FR901228 (depsipeptide).&#xD;
&#xD;
      II. Determine the toxicity of this drug in these patients. III. Correlate clinical response&#xD;
      with specific cytogenetic abnormalities in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to the presence of a specific chromosomal&#xD;
      abnormality (t[8;21] vs inv 16 vs t[15;17] vs absence of these chromosomal abnormalities).&#xD;
&#xD;
      Patients receive romidepsin IV over 4 hours on days 1, 8, and 15.&#xD;
&#xD;
      Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (complete and partial)</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events, measured using National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 2.0</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Acute Promyelocytic Leukemia (M3)</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>romidepsin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>FK228</other_name>
    <other_name>FR901228</other_name>
    <other_name>Istodax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed acute myeloid leukemia (AML) defined by the WHO&#xD;
             classification&#xD;
&#xD;
          -  Initial diagnosis with either of the following:&#xD;
&#xD;
               -  Bone marrow or peripheral blood myeloblasts of at least 20%,&#xD;
&#xD;
               -  Recurring genetic abnormalities (e.g., t[8;21], inv 16, or t[16;16]) and&#xD;
&#xD;
               -  Bone marrow blast percentage less than 20%&#xD;
&#xD;
          -  Relapsed or refractory disease defined by 1 of the following:&#xD;
&#xD;
               -  Under 60 years of age and in second relapse or greater,&#xD;
&#xD;
               -  Over 60 years of age and in first relapse,&#xD;
&#xD;
               -  Acute promyelocytic leukemia that has relapsed despite prior tretinoin and&#xD;
                  arsenic therapy,&#xD;
&#xD;
               -  Primary refractory AML for which no standard therapy exists&#xD;
&#xD;
          -  Patients who are over 60 years of age with previously untreated disease and who refuse&#xD;
             conventional chemotherapy are eligible&#xD;
&#xD;
          -  Patients who are over 60 years of age and in first relapse and poor medical candidates&#xD;
             for reinduction chemotherapy or who refuse conventional chemotherapy are eligible&#xD;
&#xD;
          -  Not medically appropriate for OR refused curative bone marrow or stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  No CNS leukemia&#xD;
&#xD;
          -  ECOG 0-2 OR Karnofsky 60-100%&#xD;
&#xD;
          -  LVEF at least 40% by MUGA&#xD;
&#xD;
          -  QTc interval less than 500 msec by EKG&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior allergic reactions attributed to compounds of similar chemical or biological&#xD;
             composition to FR901228 (depsipeptide)&#xD;
&#xD;
          -  No concurrent uncontrolled illness&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  At least 4 weeks since prior autologous stem cell or bone marrow transplantation&#xD;
&#xD;
          -  No prior allogeneic stem cell or bone marrow transplantation&#xD;
&#xD;
          -  No concurrent biologic agents&#xD;
&#xD;
          -  At least 2 weeks since prior chemotherapy (6 weeks for mitomycin and nitrosoureas)&#xD;
&#xD;
          -  No concurrent chemotherapy, concurrent hydroxyurea allowed during the first course of&#xD;
             study therapy to control hyperleukocytosis&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent drugs known to have histone deacetylase inhibitor activity (e.g., sodium&#xD;
             valproate)&#xD;
&#xD;
          -  No other concurrent antineoplastic agents&#xD;
&#xD;
          -  No prior FR901228 (depsipeptide)&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olatoyosi Odenike</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>December 3, 2015</last_update_submitted>
  <last_update_submitted_qc>December 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

